- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | HeartBeam: Positive Studiendaten für tragbares EKG-Gerät zur Herzinfarktdiagnostik | 1 | Investing.com Deutsch | ||
| 26.10. | HeartBeam gains FDA acceptance into device acceleration program | 1 | Investing.com | ||
| 26.10. | HeartBeam: FDA nimmt 3D-EKG-System in Beschleunigungsprogramm TAP auf | 5 | Investing.com Deutsch | ||
| 15.10. | HeartBeam, Inc.: HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients | 605 | Business Wire | HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium HeartBeam will lead the HEART-CHECK Study, one of the... ► Artikel lesen | |
| 06.10. | FDA-Erfolg für Heartbeam: H.C. Wainwright bleibt bei 'Neutral'-Einstufung | 2 | Investing.com Deutsch | ||
| 06.10. | Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news | 2 | Investing.com | ||
| 05.10. | HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System | 2 | Benzinga.com | ||
| HEARTBEAM Aktie jetzt für 0€ handeln | |||||
| 05.10. | HeartBeam: Aktie schießt nach beschleunigter FDA-Zulassung um 56 % in die Höhe | 2 | Investing.com Deutsch | ||
| 05.10. | HeartBeam-Aktie schießt nach FDA-Sonderstatus für Herzinfarkt-Tool in die Höhe | - | Investing.com Deutsch | ||
| 05.10. | FDA Grants Breakthrough Device Designation For HeartBeam System For Heart Attack Detection | 2 | RTTNews | ||
| 05.10. | HeartBeam erhält von der FDA "Breakthrough"-Status für Herzinfarkt-Diagnosetool | 3 | Investing.com Deutsch | ||
| 21.09. | HeartBeam shifts focus to heart attack detection technology | 4 | Investing.com | ||
| 14.08. | HeartBeam schließt Aktienverkaufsvereinbarung über 25 Millionen US-Dollar mit Titan Partners | 3 | Investing.com Deutsch | ||
| 14.08. | HeartBeam, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.08. | HeartBeam Q2 slides show clinical progress despite wider Q2 2026 loss | 2 | Investing.com | ||
| 13.08. | HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript | 1 | Benzinga.com | ||
| 13.08. | Heartbeam Aktie: Quartalsverlust belastet nachbörslichen Kurs | 1 | Investing.com Deutsch | ||
| 14.07. | HeartBeam receives patent for multi-modal cardiac sensing device | 1 | Investing.com | ||
| 02.07. | HeartBeam, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | HeartBeam, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 14,200 | +1,43 % | Eckert&Ziegler vor dem Quartalsbericht: Warum die Aktie wieder Fahrt aufnimmt | ||
| UNITEDHEALTH | 365,20 | +0,11 % | US-Börse: 46 Aktien schufen $45,5 Billionen | © Foto: Lee Woodgate - Ikon ImagesEine Studie des US-Finanzwissenschaftlers Hendrik Bessembinder kommt zu dem Schluss, dass die Hälfte des in den letzten 100 Jahren an der US-Börse erwirtschafteten... ► Artikel lesen | |
| TELADOC HEALTH | 8,700 | +0,76 % | Teladoc Health, Inc.: Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 | ||
| SERNOVA BIOTHERAPEUTICS | 0,070 | -0,57 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| DEXCOM | 79,00 | +0,25 % | DexCom Inc. Q3 Sales Increase | WASHINGTON (dpa-AFX) - DexCom Inc. (DXCM) reported earnings for third quarter of $275.1 millionThe company's earnings came in at $275.1 million, or $0.72 per share. This compares with $283.8... ► Artikel lesen | |
| CERENOME | 0,688 | -32,68 % | Cerenome Unit Signs National Reimbursement Agreement With Aetna; Shares Fall | ||
| RESMED | 215,30 | +0,51 % | Resmed Inc Q1 Income Advances | WASHINGTON (dpa-AFX) - Resmed Inc (RMD.AX) released a profit for its first quarter that Increases, from last yearThe company's bottom line totaled $418.413 million, or $2.92 per share. This... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,870 | -1,58 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 16,300 | -4,12 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,376 | +4,04 % | Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India | CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile... ► Artikel lesen | |
| QUIDELORTHO | 11,630 | -9,03 % | QuidelOrtho expects over $80M in 2027 annual savings as it narrows 2026 revenue to $2.52B-$2.54B | ||
| VERU | 2,190 | -0,45 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data | ||
| LIFEWARD | 6,150 | 0,00 % | 6,4 Millionen US-Dollar pro Patient: Warum Medtronic, Lifeward und NurExone an drei Stufen der Rückenmarksversorgung ansetzen | ||
| CLOVER HEALTH INVESTMENTS | 4,090 | -1,68 % | Needham reiterates Clover Health stock rating on profitability |
HEARTBEAM INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,008 (-1,91 %) liegt der Kurs bei 0,416 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEARTBEAM INC finden Sie auf Wallstreet Online.